- Home
- WGS vs GLPG Comparison
WGS vs GLPG Comparison
Compare WGS & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGS
- GLPG
- Stock Information
- Founded
- WGS 2017
- GLPG 1999
- Country
- WGS United States
- GLPG Belgium
- Employees
- WGS N/A
- GLPG N/A
- Industry
- WGS Retail: Computer Software & Peripheral Equipment
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- WGS Technology
- GLPG Health Care
- Exchange
- WGS Nasdaq
- GLPG Nasdaq
- Market Cap
- WGS 2.4B
- GLPG 2.1B
- IPO Year
- WGS N/A
- GLPG 2005
- Fundamental
- Price
- WGS $132.54
- GLPG $33.36
- Analyst Decision
- WGS Strong Buy
- GLPG Sell
- Analyst Count
- WGS 7
- GLPG 4
- Target Price
- WGS $99.29
- GLPG $25.33
- AVG Volume (30 Days)
- WGS 666.9K
- GLPG 255.3K
- Earning Date
- WGS 10-28-2025
- GLPG 10-29-2025
- Dividend Yield
- WGS N/A
- GLPG N/A
- EPS Growth
- WGS N/A
- GLPG N/A
- EPS
- WGS 0.05
- GLPG N/A
- Revenue
- WGS $362,321,000.00
- GLPG $323,674,692.00
- Revenue This Year
- WGS $35.84
- GLPG N/A
- Revenue Next Year
- WGS $18.46
- GLPG N/A
- P/E Ratio
- WGS $2,732.19
- GLPG N/A
- Revenue Growth
- WGS 48.70
- GLPG 5.43
- 52 Week Low
- WGS $28.86
- GLPG $22.36
- 52 Week High
- WGS $134.43
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- WGS 70.44
- GLPG 59.82
- Support Level
- WGS $125.00
- GLPG $30.88
- Resistance Level
- WGS $134.43
- GLPG $33.25
- Average True Range (ATR)
- WGS 5.80
- GLPG 0.75
- MACD
- WGS -0.57
- GLPG -0.02
- Stochastic Oscillator
- WGS 90.63
- GLPG 97.25
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.